Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985879 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
NCT02985879 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 378 participants.
The verdict
NCT02985879, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
Study Summary
The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).
Interventions
- DRUG Placebo
- DRUG ABBV-8E12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985879
The ClinicalTrials.gov registry entry for NCT02985879 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02985879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985879 about?
NCT02985879 is a clinical study titled "A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)". The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).
What is the current status of trial NCT02985879?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2016-12-12. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT02985879?
The interventions under investigation include: Placebo (DRUG), ABBV-8E12 (DRUG).
Who is sponsoring clinical trial NCT02985879?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.